Hepatitis Control Plan

Where will we make the difference in the next 5 years?

Antons Mozalevskis, MD
WHO Regional Office for Europe

VHPB meeting
5th June 2015, London
National policy: MS reporting national strategy or plan on prevention and control of viral hepatitis (2013)
National policy: developments in 2015

- WHO Consolidated Review of the National Hepatitis Plan for Turkey, March 2015
- WHO-GHP and WHO-EURO joint assistance on Georgia National Hepatitis C Elimination Plan – ongoing
- Support for National Hepatitis Strategies planned for Albania, Lithuania
- More to come...
Future directions

- Increase political commitment (RC) →
- Development of national policies →
- Sustainable changes – fully integrated into Health Systems – principles of Universal Health Coverage (UHC)
- Access to
  - Prevention
  - Diagnosis
  - Treatment
    Integrated with relevant programmes (HIV/AIDS, etc.)
- Facilitate a broad network of partners at global, regional and national levels
Awareness and advocacy

• Recognising the World Hepatitis Day, July 28th
Partnerships

• Strengthening partnership with European Commission, ECDC, EMCDDA

• Collaboration with civil society partners
  – Partnership with World Hepatitis Alliance, ELPA and other civil society organisations
  – Civil Society Reference Group?
First World Hepatitis Summit

- September 2–4, 2015, Glasgow
- Organised by WHO, World Hepatitis Alliance and the Scottish Government
- Bringing together policy-makers with civil society
- 14 European focus countries funded participation, all WHO Member States invited and encouraged to participate
- WHO-EURO and US CDC parallel sessions on Strategic Information for Planning
Data for policy and action

• “Strengthening viral hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014)” – ready for publication
• Harmonising case definitions and reporting
• Collaboration with ECDC enhanced viral hepatitis surveillance network
• WHO guidance on viral hepatitis surveillance
• Prevalence estimation studies and seroprevalence survey in collaboration with ECDC?
Care and treatment

• Determination of national hepatitis screening, care and treatment cascades
• Improving treatment access and equality
  – WHO Essential Medicines List 2015
Lessons learned from HIV/AIDS response

• Strong standardised surveillance (jointly with ECDC)
• Awareness of the problem (general population, risk groups, health care authorities and providers)
• Advocacy, activism, lobbying from patient led organizations
• Public health approach to treatment